Fig. 1
From: Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
CONSORT diagram depicting patient enrolment in the EPITAX, DDP, and PETREMAC clinical trials, and the number of pretreatment samples collected and successfully analyzed in the current study. “*” symbol indicates the following: three patients were diagnosed with two synchronous primary tumors each: one patient diagnosed with two HER2-negative tumors expressing ER ≥ 10% and two patients diagnosed with two separate HER2 + tumors each